A review of chemotherapeutic approaches to the treament of Cryptosporidiosis

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 297-305

  Armson, Anthony ^a   Thompson, R C Andrew ^a   Reynoldson, James A ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Apicomplexa; Chemotherapy; Coccidia; Cryptosporidium parvum

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; AGMATINE; ALBENDAZOLE; AZITHROMYCIN; BENZIMIDAZOLE DERIVATIVE; CALCIMYCIN; CHLOROQUINE; COCCIDIOSTATIC AGENT; CYCLODEXTRIN; DICLOXACILLIN; DIHYDROFOLATE REDUCTASE; DOXYCYCLINE; LASALOCID; MACROLIDE; MADURAMICIN; MONENSIN; NARASIN; NITAZOXANIDE; ORNITHINE DECARBOXYLASE; PAROMOMYCIN; POLYAMINE; PYRIMETHAMINE; SALINOMYCIN; SPIRAMYCIN; SULFAQUINOXALINE; THYMIDYLATE SYNTHASE; TOLTRAZURIL; TRIMETHOPRIM; TUBULIN; UNINDEXED DRUG;

APICOPLAST; BIOSYNTHESIS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE SEVERITY; DRUG DESIGN; DRUG TARGETING; HELMINTH; HELMINTHIASIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 2442468577     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.2.297     Document Type: Review

References (69)

1. Dusnmore JD, Thompson RCA, Jue Sue LP, Hobbs RP. Introductory Veterinary Parasitology. Murdoch University, Perth Western Australia (1998).
2. Beaver PC, Jung RC, Cupp EW. Clinical Parasitology. Lea RA, Febiger B. PA, USA, (1984)
3. Fayer R, Speer CA, Dubey JP. The General Biology of Cryptosporidium in Cryptosporidium and Cryptosporidiosis. Fayer R (Ed.). CRC Press, NY, USA, (1997).
4. Casemore DP, Wright SE, Coop RL. In: Cryptosporidium and Cryptosporidiosis. Fayer R (Ed.). CRC Press, NY, USA, (1997).
5. Bush AO, Fernández JC, Esch GW, Seed JR. Parasitism: the Diversity and Ecology of Animal Parasites. Cambridge University Press, Cambridge, UK, (2001).
6. Rose JB, Lisle JT, LeChavaller M. Waterhorne Cryptosporidiosis: Incedence, Outbreaks and Treatment Strategies in Cryptosporidium and Cryptosporidiosis. Fayer R (Ed.). CRC Press, NY, USA (1997).
7. Woods KM, Nesterenko, MV, Upton, SJ. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Porasitol. 90, 603-615 (1996).
8. Armson A, Meloni BP, Reynoldson JA, Thompson RCA. Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol. Lett. 178, 227-233 (1999a).
9. Fayer R, Fetterer R. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J. farasitol. 81, 794-795 (1995).
10. Rehg JE. Anticryptosporidial activity of lasalocid and other ionophorous antibiotics in immunosuppressed rats. J. Infect. Dis. 168, 1566-1569 (1993).
11. Carreno RA, Martin DS, Barta JR. Cryptosporidium is more closely related to gregarines than to coccidia as shown by phylogenetic analysis of apicomplexan parasites inferred using small-subunit ribosomal RNA gene sequences. Parasitol. Res. 85, 899-904 (1999).
12. Hijjawi NS, Meloni BP, Morgan UM, Olson ME, Thompson RCA. Successful in vitro cultivation of Cryptosporidium andersoni with evidence for the existence of novel extracellular stages in the Cryptosporidium life cycle. Int. J. Parasitol, 32, 1719-1726 (2002).
13. Marechal E, Cesbron-Delauw MF. The apicoplast: a new member of the plastid family. Trends Plant Sci. 6, 200-204 (2001).
14. Tetley L, Brown SMA, McDonald V, Coombs GH. Ultrastructural analysis of the sporozoite of Cryptosporidium parvum. Microbiology 144, 3249-3255 (1998).
15. Zhu G, Marchewka MJ, Keithly JS. Cryptosporidium parvum appears to lack a plastid genome. Microbiology 146, 315-321 (2000).
16. Armson A, MacDonald LM, Thompson RCA Reynoldson JA. Inhibition of two plastid pathways in Cryptosporidium parvum cattle strain. (2003) (In Press).
17. Roberts CW, Roberts F, Lyons RE et al. The shikimate pathway and its branches in apicomplexan parasites. J. Infect. Dis. 185, S25-36 (2002).
18. Blagbum BL, Soave R. Prophylaxis and chemotherapy-human and animal. Cryptosporidium and cryptosporidiosis. Fayer R (Ed.). CRC Press, NY, USA, (2002).
19. Goodman, Gilman's. The Pharmacological Basis of Therapeutics. Hardman Joel G, Limbird Lee E (Eds). McGraw-Hill, NY, USA, (1996).
20. Lindsay DS, Blagburn BL. Antiprotozoal Drugs in Veterinary and Pharmacology and Therapeutics (8th Edition). Adams HR (Ed.). Iowa State University Press, IO, USA, (2001).
21. Blagburn BL, Sunderman CA, Lindsay DS, Hall JE, Tidwell RR. Inhibition of Cryptosporidium parvum in neonatal Hsd: (ICR)BR Swiss mice by polyether ionophores and aromatic amidines. Antimicrob. Agents Chemoth. 35, 1520-1523 (1991).
22. Kimata I, Uni S, Iseki M. Chemotherapeutic effect of azithromycin and lasalocid on Cryptosporidium infection in mice. J. Protozol. 38, 232S-233S (1991).
23. Lemeteil D, Roussel F, Favennec L, Ballet JJ, Brasseur P. Assessment of candidiate anticryptosporidial agents in an immunosuppressed rat model. J. Infect. Dis. 167, 766-768 (1992).
24. Hardman Joel G, Limbird Lee E. Chemotherapy of microbial diseases. In: The Pharmacological Basis of Therapeutics. Chambers HF, Sande MA (Ed.). McGraw-Hill, NY, USA, (1996).
25. Fayer R, Ellis W. Paromomycin is effective as a prophylaxis for cryptosporidiosis in dairy calves. J. Parasitol. 79, 771-774 (1993).
26. Sreter T, Szell Z, Varga I. Anticryptosporidial prophylactic efficacy of enrofloxacin and paromomycin in chickens. J. Parasitol. 88, 209-211 (2002).
27. Tzipori S. Cryptosporidiosis: laboratory investigations and chemotherapy. Adv. Parasitol. 40, 187-221 (1998).
28. Mead J. Cryptosporidiosis and the challenges of chemotherapy. Drug Resist. Updates 5, 47-57 (2002).
29. Leitch GJ, He Q. Putative anticryptosporidial agents tested with an immunodeficient mouse model. Antimicrob. Agents Chemother 38, 865-867(1994).
30. Cama VA, Marshall MM, Shubitz LF, Ortega YR, Sterling CR. Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin. J. Eukaryot. Microbiol. 41, 25S (1994).
31. Lemeteil D, Roussel F, Favennec L. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. J. Infect. Dis. 167, 766-768 (1993).
32. Rehg JE. Activity of azithromycin against Cryptosporidia in immunosuppressed rats. J. Infect. Dis. 163, 1293-1296 (1991).
33. Castro-hermida JA, González-Losada Y, Freire-Santos F et al. Efficacy of b-cyclodextrin against experimental cryptosporidiosis in neonatal lambs. J. Parasitol. 88, 185-187 (2002).
34. Mention K. Assessment of the Antiprotozoal Activity of some Tubulin Inhibitors Following Cyclodextrin Complexation. PhD thesis, Murdoch University, Perth WA, Australia (2002).
35. Cabello RR, Guerrero LR, Garcia MRM, Cruz AG. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. Roy. Soc. Trop. Med. Hyg. 91, 701-703 (1997).
36. Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with aquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56, 637-639 (1997).
37. Coombs GH, Maer S. Recent advances in the search for new anticoccidial drugs. Internat. J. Parasitol. 32, 497-508 (2002).
38. Meloni BP, Thompson RCA. Simplified methods for obtaining purified oocysts from mice and for growing Cryptosporidium parvum in vitro. J. Parasitol. 82, 757-762 (1996).
39. Upton SJ, Tilley M, Brillhart DB. Comparative development of Cryptosporidiumparvum (Apicomplexa) in 11 continuous host cell lines. FEMS Microbiol. Lett. 118, 233-236 (1994a).
40. Upton SJ, Tilley M, Brillhart DB. Comparative development of Cryptosporidiumparvum in MDBK and HCT-8 cells under select atmospheres. Biomed Lett. 49, 265-271 (1994b).
41. Upton SJ, Tilley M, Brillhart DB. Effects of select medium supplements on in vitro development of Cryptosporidiumparvum in HCT-8 cells. J. Clin. Microbiol. 33, 371-375 (1995).
42. Upton SJ, Tilley M, Nesterenko MV, Brillhart DB. A simple and reliable method of producing in vitro infections of Cryptosporidium parvum (Apicomplexa). FEMS Microbiol. Lett. 118, 45-50 (1994).
43. MacDonald LM, Sargent K, Armson A, Thompson RCA, Reynoldson JA. The development of a real-time quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy. Molecul. Biochem. Parasitol. 121, 279-282 (2002).
44. Woods KM, Nesterenko MV, Upton SJ. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Micro. Letts 128, 89-94 (1995).
45. Arrowood MJ, Jaynes JM, Healey MC. In vitro activities of lytic peptides against the sporozoites of Cryptosporidium parvum. Antimicrob. Agents Chem. 35, 224-227 (1991).
46. Moss D, Arrowood M. Quantification of Cryptosporidium parvum oocysts in mouse fecal specimens using immunomagnetic particles and two-colour flow cytometry. J. Parasitol. 87, 406-412 (2001).
47. Armson A, Sargent K, MacDonald LM, Thompson, RCA, Reynoldson JA. A comparison of the in vitro and in vivo effects of two dinitroanilines against Cryptosporidium parvum in neonatal mice. FEMS Immunol, Med. Microbiol. 26, 109-113 (1999b).
48. Griffiths JK, Moore R, Dooley S, Keusch GT, Tzipori S. Cryptosporidium parvum infection of Caco-2 cell monolayers; induces an apical monolayer defect, selectively increases transmonolayer permeability and causes epitheleial cell death. Infect. Immun. 62, 4506-4514 (1994).
49. Lindsay DS. Laboratory models of cryptosporidiosis. In: Cryptosporidium and cryptosporidiosis. Fayer R. (Ed.). CRC Press, NY, USA (1997).
50. Rehg JE. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. J. Infect. Dis. 170, 934-938 (1994).
51. Yang S, Healey MC. The immunosuppresive effects of dexamethasone administered in drinking water to C57BL/6N mice infected with Cryptosporidium parvum. J. Parasitol. 79, 626-630 (1993).
52. Tzipori S, Campbell I, Angus T. The therapeutic effect of 16 antimicrobial agents on Cryptosporidium infection in mice. Aust. J. Exp. Biol. Med, Sc. 60, 187-190 (1982).
53. Rohlman S, Kuhls VC, Mosier DA, Crawford DL, Hawkins DR, Abrams VL. Therapy with atovaquone for Cryptosporidium parvum infection in neonatal severe combined immunodefficiency mice. J. Infect. Dis. 168, 258-260 (1993).
54. Tzipori S, Rand W, Griffiths JK, Widmer G, Crabb J. Model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diag. Lab. Immunol. 1, 450-463 (1994).
55. Mead JR, You X, Pharr JE, Belenkaya Y, Arrowood MJ, Fallon MT, Schinazi RF. Evaluation of maduramycin and alborixin in a SCID mouse model of chronic cryptosporidiosis. Antimicrob. Agents Chemother. 39, 854-858 (1995).
56. Favennec L. Physiopathologic and therapeutic studies in in vitro and in vivo models of Cryptosporidium parvum infection. J. Euk. Microbiol. 44, 69S-70S (1997).
57. Nelson R, Rosowsky A. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicrob. Agents Chem. 45, 3293-3303 (2001).
58. Zumla A, Croft SL. Chemotherapy and immunity in opportunistic parasitic infections in AIDS. Parasitology 105, S93-S101 (1992).
59. Keithly JS, Zhu G, Upton SJ, Woods KM, Martinez MP, Yarlett N. Polyamine biosynthesis in Cryptosporidiumparvum and its implications for chemotherapy. Molecular Biochem. Parasitology 88, 35-42 (1997).
60. Moore D, Waters WR, Wnnemuehler MJ, Harp, JA. Treatment with agmatine inhibits Cryptosporidium parvum infection in infant mice. J. Parasitol. (2001).
61. Meloni BP, Thompson RCA, Reynoldson JA, Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans. Roy. Soc. Trop. Med. Hyg. 84, 375-379 (1990).
62. Morgan UM, Reynoldson JA, Thompson RCA. Activities of several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro. Antimicrob. Agents Chemother. 37, 328-331 (1993).
63. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD. Antiprotozoal activities of benzimidazoles and correlations with tubulin sequence. Antimicrob. Agents Chemother. 38, 2086-2090 (1994).
64. Armson A, Kamau SW, Grimm F et al. A comparison of the effects of a benzimidazole and the dinitroanilines against Leishmania infantum. Acta Trop. 73, 303-311 (1999c).
65. Arrowood MJ, Mead JR, Xie LT, You XD. In vitro anticryptosporidial activity of dinitroaniline herbicides. FEMS. Microbiol. Lett. 136, 245-249 (1996).
66. Chan M-Y, Grogl M, Chen C-C, Bienen EJ, Fong D. Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans. Proc. Natl Acad. Sci. USA 90, 5657-5661 (1993).
67. Callahan HL, Kelley C, Pereira T, Grogl M. Microtubule Inhibitors: Structure-activity analyses suggest rational models to identify potentially active compounds. Antimicrob. Agents Chemother. 40, 947-952 (1996).
68. Benbow JW, Bernberg EL, Korda A, Mead JR. Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis. Antimicrob. Agents Chemother. 42, 339-343 (1998).
69. Armson A, Menon K, O'Hara A et al. Efficacy of oryzalin and associated histological changes in Cryptosporidium-infected neonatal rats. Parasitology 125, 113-117 (2002).